Insider Selling: Beigene Ltd (NASDAQ:BGNE) CMO Sells $336,850.00 in Stock

Share on StockTwits

Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 2,500 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $134.74, for a total value of $336,850.00. Following the sale, the chief marketing officer now directly owns 328,873 shares of the company’s stock, valued at $44,312,348.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jane Huang also recently made the following trade(s):

  • On Monday, July 29th, Jane Huang sold 10,130 shares of Beigene stock. The shares were sold at an average price of $134.54, for a total value of $1,362,890.20.
  • On Thursday, June 27th, Jane Huang sold 430 shares of Beigene stock. The shares were sold at an average price of $124.52, for a total value of $53,543.60.
  • On Monday, May 20th, Jane Huang sold 300 shares of Beigene stock. The shares were sold at an average price of $130.12, for a total value of $39,036.00.

Shares of Beigene stock opened at $141.19 on Friday. The stock has a 50-day moving average price of $129.48 and a 200 day moving average price of $129.91. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.46 and a quick ratio of 7.47. Beigene Ltd has a 1 year low of $105.19 and a 1 year high of $182.30.

Beigene (NASDAQ:BGNE) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.01) by $1.58. The firm had revenue of $243.35 million during the quarter, compared to the consensus estimate of $65.58 million. Beigene had a negative return on equity of 38.41% and a negative net margin of 153.32%. The business’s revenue for the quarter was up 360.8% on a year-over-year basis. During the same period in the prior year, the business earned ($2.92) EPS. On average, equities analysts forecast that Beigene Ltd will post -12.27 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Capital Investment Advisory Services LLC acquired a new position in Beigene in the 2nd quarter worth about $26,000. Advisor Group Inc. increased its position in Beigene by 301.4% in the 4th quarter. Advisor Group Inc. now owns 285 shares of the company’s stock worth $40,000 after purchasing an additional 214 shares during the last quarter. Quadrant Capital Group LLC increased its position in Beigene by 131.8% in the 1st quarter. Quadrant Capital Group LLC now owns 364 shares of the company’s stock worth $47,000 after purchasing an additional 207 shares during the last quarter. Riverhead Capital Management LLC increased its position in Beigene by 28.6% in the 2nd quarter. Riverhead Capital Management LLC now owns 450 shares of the company’s stock worth $56,000 after purchasing an additional 100 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Beigene by 1,500.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 592 shares of the company’s stock worth $73,000 after purchasing an additional 555 shares during the last quarter.

BGNE has been the subject of several analyst reports. Sanford C. Bernstein initiated coverage on Beigene in a report on Tuesday, June 4th. They set an “outperform” rating and a $201.00 target price for the company. Zacks Investment Research downgraded Beigene from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Maxim Group set a $170.00 target price on Beigene and gave the company a “buy” rating in a report on Friday, August 9th. BidaskClub raised Beigene from a “hold” rating to a “buy” rating in a research note on Wednesday, July 31st. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Beigene in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $181.28.

About Beigene

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Recommended Story: Diversification in Investing

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
SBA Communications Co.  Shares Sold by Meeder Asset Management Inc.
SBA Communications Co. Shares Sold by Meeder Asset Management Inc.
Cactus Inc  Position Increased by Meeder Asset Management Inc.
Cactus Inc Position Increased by Meeder Asset Management Inc.
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA


© 2006-2019 Ticker Report